Prostate carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from epithelial cells of the prostate gland.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Prostate carcinoma
- Therapeutic area
- Oncology
- prostate carcinoma
- carcinoma of prostate
- carcinoma of prostate gland
- carcinoma of the prostate
- prostate carcinoma
- prostate gland carcinoma
- cancer of prostate
- cancer of the prostate
- prostate cancer
- prostate cancer, NOS
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0005159
- Parent condition
- MONDO:0004993
Related records
Broader conditions (19)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Human disease
- Male reproductive organ cancer
- Male reproductive system disorder
- Male reproductive system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Prostate cancer
- Prostate disorder
- Prostate neoplasm
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (17)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Adenosquamous prostate carcinoma
- Castration-resistant prostate carcinoma
- Familial prostate carcinoma
- Grade III prostatic intraepithelial neoplasia
- Hormone-resistant prostate carcinoma
- Lymphoepithelioma-like acinar prostate adenocarcinoma
- Metastatic prostate carcinoma
- Primary prostate urothelial carcinoma
- Prostate adenocarcinoma
- Prostate adenoid cystic carcinoma
- Prostate small cell carcinoma
- Prostate squamous cell carcinoma
- Prostatic acinar adenocarcinoma
- Prostatic urethra urothelial carcinoma
Trials (311)
- [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
- 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
- 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
- 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
- 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
- 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
- A Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
- A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
- A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
- A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
- A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer
- A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- A Prospective, Single-centreļ¼Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis
- A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
- A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Approved drugs (19)
- Abiraterone acetate
- Apalutamide
- Autologous peripheral-blood mononuclear cells including A minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor
- Cabazitaxel
- Darolutamide
- Degarelix acetate
- Docetaxel
- Dutasteride
- Enzalutamide
- Finasteride
- Flutamide
- Isopropyl alcohol
- Leuprolide acetate
- Lidocaine hydrochloride
- Olaparib
- Radium RA 223 dichloride
- Tamsulosin hydrochloride
- Triptorelin pamoate
- Zoledronic acid
Drugs in development (94)
- Abemaciclib Phase 1
- Abiraterone Phase 3
- ASG-5ME Phase 1
- Aspirin Phase 2
- Avelumab Phase 1
- AZD-8186 Phase 1
- Bendamustine Phase 1
- Berzosertib Phase 2
- Bicalutamide Phase 3
- Bicarbonate Early phase 1
- Bintrafusp alfa Phase 1
- Calcitriol Phase 2
- Carboplatin Phase 2
- Cedazuridine Phase 1
- Cetrelimab Phase 1
- Cholecalciferol Phase 3
- Cixutumumab Phase 2
- Cyclophosphamide Phase 2
- Dapagliflozin Phase 1
- Davamotecan pegadexamer Phase 2
Other linked drugs (1)
- Choline